WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
China's Top Political Advisory Body Holds Press Conference Ahead of Annual SessionChina Focus: China strives for vitality after COVID management downgradeMainland calls for peaceful development of crossMacao's electoral affairs commission for chief executive election takes officeEmbassy welcomes 'home' overseas ChineseNumber of flights gradually increasingEconomic Watch: China remains popular destination for foreign investmentCPC Leadership Discusses Draft Gov't work ReportChinese peacekeepers to DRC awarded UN Peace MedalBuild a new world economic order with emerging forces: Italian economist
2.8103s , 6515.984375 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Culture Corner news portal